Condition deep-dive · 6 min read

Shingles and post-herpetic neuralgia — supplement protocol and prevention

Updated 2026-05-17 · Reviewed by SupplementScore editors · No sponsorships

Shingles (herpes zoster) is the reactivation of varicella zoster virus in dorsal root ganglia. About 10–18% of cases develop post-herpetic neuralgia (PHN) — persistent neuropathic pain in the same dermatome after the rash heals. The supplement evidence base is thin compared to the prevention and treatment interventions that actually work: the recombinant zoster vaccine (Shingrix), prompt antiviral therapy within 72 hours of rash onset, and standard neuropathic pain management for PHN. This page covers where supplements have a real role (mostly adjunctive in chronic PHN), and where the marketing runs ahead of evidence (most "shingles support" products).

Read this first. If you have an acute shingles rash, start antiviral therapy (valacyclovir, famciclovir, or acyclovir) within 72 hours of onset — this reduces PHN risk and shortens illness. See a clinician same-day. Shingles in or near the eye (herpes zoster ophthalmicus) is an ophthalmologic emergency. Disseminated zoster (cross-dermatomal spread) is a medical emergency in immunocompromised patients. Supplements do not substitute for antivirals.

Prevention — vaccination is the high-yield intervention

The recombinant zoster vaccine (Shingrix, two doses, 97% efficacy in adults 50+ and 91% in 70+) is the single highest-yield intervention for preventing both shingles and PHN. CDC recommends it for adults aged 50+ and for immunocompromised adults 19+. Supplement protocols do not approach this efficacy. If you've had shingles already, vaccination is still recommended to prevent recurrence.

Supplement options — where evidence is real

Tier 2 evidence · Adjunct in active flare

L-Lysine (during acute flare)

1000 mg TID during acute flare for 5–7 days; consider 500 mg BID for recurrent HSV / chronic suppression in different VZV-context

Lysine inhibits arginine-dependent viral replication in herpesvirus family. Trial evidence is strongest for recurrent HSV-1/HSV-2 outbreaks (different virus in same family). Some clinicians extend the rationale to VZV/shingles, though direct trial evidence is limited. Reasonable adjunct during an acute flare alongside antivirals; unlikely to substitute for them.

Tier 2 evidence · For PHN, adjunct to pharmaceuticals

Palmitoylethanolamide (PEA)

600 mg BID micronised, or 600 mg/day ultra-micronised; 8+ weeks

PEA has trial evidence for neuropathic pain including PHN. Reasonable adjunct to gabapentin, pregabalin, or duloxetine in chronic PHN. Effect is modest but additive to pharmaceuticals.

Tier 2 evidence · Adjunct

Alpha-lipoic acid (for chronic PHN)

600 mg/day, 8–12 weeks

Strong evidence in diabetic peripheral neuropathy; smaller evidence base in PHN specifically. Reasonable adjunct in chronic PHN given low harm profile and shared neuropathic-pain mechanisms.

Tier 2 evidence · Immune support

Vitamin C (moderate dose)

500–1000 mg/day during acute flare; 200–500 mg/day chronically if intake is low

Modest evidence of pain reduction during acute shingles with high-dose vitamin C (oral or IV in some trials — Schencking 2010 IV trial showed pain reductions). Quality of evidence is mixed. Low-harm adjunct during an acute flare.

Tier 2 evidence · Adjunct

Methylcobalamin (Vitamin B12)

1000–1500 mcg/day sublingual or oral; or IM injection per primary care

Older Japanese trials of high-dose methylcobalamin (sometimes by injection) showed PHN benefit. Modern systematic reviews call the evidence preliminary but supportive. Reasonable in older adults with PHN, particularly those with marginal B12 status.

Tier 2 evidence · Background nutrition

Zinc — particularly in older adults

15–30 mg elemental zinc daily; check serum zinc if deficient

Older adults commonly have marginal zinc status, which affects immune function and may influence shingles severity. Reasonable backstop, particularly if dietary intake is limited.

Pharmaceutical and procedural options that outperform supplements

Recombinant zoster vaccine (Shingrix) — the single highest-yield intervention; 90%+ efficacy at preventing shingles and PHN.
Antiviral therapy within 72 hours — valacyclovir 1 g TID × 7 days (preferred) or famciclovir; reduces PHN risk and shortens illness.
Topical lidocaine 5% patch — first-line for PHN; minimal systemic effect.
Topical capsaicin 8% patch (Qutenza, single application by clinician) — for established PHN.
Gabapentin / pregabalin — first-line for PHN.
Tricyclic antidepressants (nortriptyline preferred over amitriptyline) — effective for PHN, particularly in patients without prominent autonomic side-effect concerns.
Pain psychology / CBT — for chronic PHN; reduces pain interference and improves function.

What to skip

"Immune boost" combination products marketed for shingles — typically sub-therapeutic blends; don't substitute for vaccination or antivirals.
High-dose monolaurin and "antiviral" botanical stacks as a substitute for antivirals — antiviral therapy is the time-critical intervention; supplements are adjunctive at best.
Topical "natural" capsaicin creams at low concentration — the 8% patch is the trial-cited form; lower-concentration creams have weaker evidence and ongoing application is irritating.
Long-term opioids for chronic PHN — typically ineffective for chronic neuropathic pain; risk profile dominates.
Self-treating zoster ophthalmicus with supplements — same-day ophthalmology evaluation is mandatory; supplements do not substitute.
Lysine megadosing (>3 g/day chronically) — no added benefit; potential interactions with calcium handling.

What to track

During acute flare: rash extent, pain trajectory, completion of antiviral course. After healing: presence and severity of PHN at 30 days, 90 days, and beyond. PHN by definition is pain persisting more than 90 days after rash onset. For chronic PHN, track pain numeric rating, sleep, and functional interference. Reassess any supplement intervention at 8–12 weeks; if no benefit, discontinue.

Practical quick-start. If you're 50+ and unvaccinated, get Shingrix (two doses, 2–6 months apart). If you have an active rash, see a clinician same-day for antivirals (within 72 hours window). If you have established PHN: pharmaceutical first-line (gabapentin or pregabalin; topical lidocaine 5%); add PEA 600 mg BID and ALA 600 mg/day as adjuncts; consider methylcobalamin. Don't substitute supplements for vaccination or antivirals.

Educational reference, not medical advice. Shingles rashes involving the eye, ear, or extensive areas need urgent evaluation. Immunocompromised patients (chemotherapy, HIV, transplant, biologics) require specialist care.